
Javier F Torres-Roca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/80979/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncology, The, 2017, 18, 202-211.	10.7	377
2	A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 489-496.	0.8	283
3	Systems Biology Modeling of the Radiation Sensitivity Network: A Biomarker Discovery Platform. International Journal of Radiation Oncology Biology Physics, 2009, 75, 497-505.	0.8	228
4	Prediction of Radiation Sensitivity Using a Gene Expression Classifier. Cancer Research, 2005, 65, 7169-7176.	0.9	197
5	Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research, 2012, 18, 5134-5143.	7.0	174
6	The future of personalised radiotherapy for head and neck cancer. Lancet Oncology, The, 2017, 18, e266-e273.	10.7	168
7	Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1399-1404.	0.8	127
8	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 631-638.	0.8	102
9	The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget, 2015, 6, 34414-34422.	1.8	100
10	Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. International Journal of Radiation Oncology Biology Physics, 2015, 92, 837-842.	0.8	82
11	Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncology, The, 2021, 22, 1221-1229.	10.7	76
12	Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiotherapy and Oncology, 2015, 117, 159-164.	0.6	75
13	A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Personalized Medicine, 2012, 9, 547-557.	1.5	71
14	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. Journal of Thoracic Oncology, 2018, 13, 1121-1127.	1.1	59
15	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101. 274-284.	0.8	50
16	Tumour radiosensitivity is associated with immune activation in solid tumours. European Journal of Cancer, 2017, 84, 304-314.	2.8	44
17	Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine, 2019, 47, 163-169.	6.1	38
18	Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Annals of Surgical Oncology, 2019, 26, 379-385.	1.5	36

JAVIER F TORRES-ROCA

#	Article	IF	CITATIONS
19	Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy, 2012, 4, 373-382.	2.0	33
20	Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. Journal of Thoracic Oncology, 2021, 16, 428-438.	1.1	32
21	Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10. Urology, 2007, 69, 505-509.	1.0	31
22	A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy, 2006, 5, 244-250.	0.5	30
23	Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. Cancer Control, 2016, 23, 21-29.	1.8	28
24	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 473-482.	4.9	25
25	Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer TreatedÂWithÂAdjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 496-502.	0.8	24
26	Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Translational Oncology, 2021, 14, 101165.	3.7	24
27	The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro-Oncology, 2017, 19, 1145-1146.	1.2	20
28	Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia, 2021, 23, 1110-1122.	5.3	15
29	Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Reports of Practical Oncology and Radiotherapy, 2019, 24, 593-599.	0.6	13
30	The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 635-647.	0.8	11
31	Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. International Journal of Breast Cancer, 2018, 2018, 1-8.	1.2	10
32	Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. American Journal of Health Promotion, 2015, 29, 393-401.	1.7	9
33	Genomically Guided Breast Radiation Therapy: A Review of the Current Data and Future Directions. Advances in Radiation Oncology, 2021, 6, 100731.	1.2	7
34	Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: A review of the H. Lee Moffitt Cancer Center experience. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 384-390.	1.6	6
35	Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. International Journal of Genomics, 2017, 2017, 1-9.	1.6	6
36	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Management, 2018, 5, MMT02.	0.5	4

JAVIER F TORRES-ROCA

#	Article	IF	CITATIONS
37	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology, 2019, 29, 111-125.	2.2	4
38	Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. Contemporary Clinical Trials, 2014, 39, 327-334.	1.8	3
39	Genomic-adjusted radiation dose – Authors' reply. Lancet Oncology, The, 2017, 18, e129.	10.7	3
40	Genomic biomarkers for precision radiation medicine – Authors' reply. Lancet Oncology, The, 2017, 18, e239.	10.7	2
41	Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncology, 2020, 16, 2411-2420.	2.4	2
42	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. SSRN Electronic Journal, 0, , .	0.4	2
43	Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT Journal of Clinical Oncology, 2016, 34, 239-239.	1.6	2
44	Differences between colon cancer primaries and metastases utilizing a molecular assay for tumor radiosensitivity and implications for potential oligometastatic SBRT patient selection Journal of Clinical Oncology, 2015, 33, 569-569.	1.6	1
45	Personalized medicine for radiation therapy. Personalized Medicine, 2013, 10, 107-110.	1.5	0
46	Letter Response. Journal of Thoracic Oncology, 2021, 16, e28-e29.	1.1	0
47	Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose. Journal of Thoracic Oncology, 2021, 16, e48-e49.	1.1	0
48	New Biomarkers in Prostate Cancer: A Radiation Oncology Perspective. Radiation Medicine Rounds, 2011, 2, 1-10.	0.0	0
49	Radiosensensitivity index prognostic for survival with adjuvant radiation in resectable pancreatic cancer Journal of Clinical Oncology, 2015, 33, 398-398.	1.6	0
50	Radiotherapy with genomic-adjusted radiation dose – Authors' reply. Lancet Oncology, The, 2021, 22, e470-e471.	10.7	0